You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: Neuro Devices, Inc.            Topic: 107

    DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a small peptide to control autoimmune inflammation in type diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Abstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients

    SBC: Mercury Biomed LLC            Topic: 400

    Project Summary Abstract This proposal presents Phase of the plan of Mercury Biomed LLC for commercializing the new and innovative WarmSmart technology to more effectively keep patients warm during anesthetized surgery The WarmSmart technology is based on IP licensed from the University of Texas at Austin who is the academic partner for this STTR proposal WarmSmart embodies several breakthr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type Diabetes

    SBC: ONEVAX, LLC            Topic: NIAID

    Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabolism is interrupted resulting in the development of life threatening complications such as heart disease and renal failure T D affects an estimated million Americans with more than new patie ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA

    SBC: SUN NUCLEAR CORP.            Topic: 103

    Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. E training of Inmate Peer Caregivers for Enhancing Geriatric and End of life Care in Prisons

    SBC: KLEIN BUENDEL, INC            Topic: NIA

    The US has the highest incarceration rate in the world imprisoning people per The older adult segment of the prison population has more than tripled since and their health issues are common to free people who are years their senior Inmates over the age of have a death rate that is times that of prisoners aged US prison systems are facing sharply increased dema ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Identification of Small Molecule Amyloid Beta Peptide Reducing Agent

    SBC: Smart Biomolecules, Inc.            Topic: NIA

    Alzheimer s disease AD is a multifactorial heterogeneous and enormously complex disorder characterized by progressive intellectual deterioration Although remarkable advances have been made in unraveling the biological basis of the disease in the last two decades that immense knowledge has not been translated in to successful therapy With the failure of secretase inhibitors at the clinical tr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Screening for the autoimmune component of multiple sclerosis

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Multiple Sclerosis is an inflammatory neurodegenerative disease with autoimmune components that exacerbate and potentially initiate the disease Diagnosis is invasive time consuming relatively expensive and extremely difficult In fact no clear diagnostic test yet exist A major concern is that MS symptoms are identical to the symptoms of numerous other neurologic diseases OND as well as some ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government